GlobalData on MSN8h
Alector stock drops after Alzheimer’s drug fails in Phase II trial
"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
Alector turns to layoffs as Alzheimer’s drug fails
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align ...
FierceBiotech13h
UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a ...
Business Insider13h
Buy Rating Maintained for Alector Despite AL002 Setback, Focus on Promising AL001 and Strong Financials
Don't Miss our Black Friday Offers: Graig Suvannavejh’s rating is based on several strategic considerations despite the recent disappointing data for Alector’s AL002. Although the Phase 2 results for ...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
BioSpace9h
Alector’s AbbVie-Partnered Alzheimer’s Program Fails Phase II, Triggering a 17% Layoff
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
STAT22h
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2 trial
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
Alector’s Strategic Pipeline and Promising PGRN Program Justify Buy Rating Despite AL002 Setback
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...
bovnews9h
Alector Inc (ALEC) Posted -257.54% Profit Margin Last Year—Can It Hold Up?
On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $3.96 which represents a slight increase of $0.02 or 0.51% from the prior close of $3.94. The stock opened at $4.01 and ...
Alector Plummets After Alzheimer's Drug Trial Fails Primary Endpoint
Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.